Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Non-Current Deffered Revenue (2017 - 2025)

Historic Non-Current Deffered Revenue for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to $3.8 million.

  • Sutro Biopharma's Non-Current Deffered Revenue fell 7912.11% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year decrease of 7912.11%. This contributed to the annual value of $12.5 million for FY2024, which is 7651.51% down from last year.
  • Sutro Biopharma's Non-Current Deffered Revenue amounted to $3.8 million in Q3 2025, which was down 7912.11% from $6.9 million recorded in Q2 2025.
  • Sutro Biopharma's Non-Current Deffered Revenue's 5-year high stood at $90.0 million during Q2 2022, with a 5-year trough of $145000.0 in Q3 2021.
  • Over the past 5 years, Sutro Biopharma's median Non-Current Deffered Revenue value was $21.7 million (recorded in 2024), while the average stood at $39.7 million.
  • In the last 5 years, Sutro Biopharma's Non-Current Deffered Revenue crashed by 9826.68% in 2021 and then soared by 5143931.03% in 2022.
  • Over the past 5 years, Sutro Biopharma's Non-Current Deffered Revenue (Quarter) stood at $145000.0 in 2021, then skyrocketed by 61889.66% to $89.9 million in 2022, then crashed by 40.61% to $53.4 million in 2023, then tumbled by 76.52% to $12.5 million in 2024, then tumbled by 70.02% to $3.8 million in 2025.
  • Its Non-Current Deffered Revenue was $3.8 million in Q3 2025, compared to $6.9 million in Q2 2025 and $8.6 million in Q1 2025.